Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals exhibits a robust compounding business model that effectively leverages cash inflows for further deal-making, highlighting its unique position within the small- to mid-cap biotechnology sector. The company anticipates strong product launches for Filspari and Ohtuvayre, which are expected to drive significant growth alongside contributions from more stable revenue sources. These factors collectively point to a positive trajectory in Ligand’s financial performance, reinforcing a favorable outlook for the company’s stock.

Bears say

Ligand Pharmaceuticals Inc faces a negative outlook primarily due to the potential underperformance of its royalty assets, which may not meet existing expectations. Concerns regarding the durability of intellectual property for key assets, combined with the possibility that clinical-stage royalty assets may fail to receive approval, further contribute to the pessimistic assessment. Additionally, anticipated future terms of agreements may be less favorable, alongside the risk that commercial partners could encounter unforeseen challenges, potentially impacting the company's overall financial stability.

Ligand Pharmaceuticals (LGND) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $239.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $239.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.